How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

550 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

481. Systemic acyclovir reaction subsequent to acyclovir contact allergy: which systemic antiviral drug should then be used? (Abstract)

with the components of Zovirax cream (acyclovir, propylene glycol and sodium lauryl sulfate) and with other antiviral drugs. Patch tests were positive to Zovirax cream, acyclovir, valacyclovir and propylene glycol. Patch and prick tests with famciclovir were negative, but its oral administration caused an itchy erythematous dermatitis on the trunk and extremities. Our patient developed a systemic acyclovir reaction subsequent to acyclovir allergic contact dermatitis, with cross-reactions to valacyclovir (...) and famciclovir. Their common chemical structure is the 2-aminopurine nucleus. It is probably this part of the molecule that provokes both contact allergy and systemic reactions. The only antiviral drugs not having this core are foscarnet and cidofovir, and these could therefore be alternatives.

2003 Contact Dermatitis

482. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. (Abstract)

and/or famciclovir. Four of six patients with HBIG breakthrough without nucleoside analogue treatment failure yielded potentially significant HBsAg mutations post transplant. These data do not support previous reports highlighting the disappearance of HBsAg mutants in liver transplant recipients after discontinuation of HBIG. Determination of HBV genotype, as well as identification of HBV polymerase and S gene mutations in liver transplant candidates may be warranted to optimize HBV management strategies post

2003 American Journal of Transplantation

483. Antiviral drugs in chronic hepatitis B: review and meta-analysis. (Abstract)

though combination therapy with cortisone seemed to achieve very good results (remission rates ranging from 45% to 66% in patients treated). Lamivudine did not seem to furnish lasting effects in chronic hepatitis B, because many patients relapse after suspension of the treatment due to the appearance of HBV variants resistant to the drug. Contrasting results were observed with famciclovir. Treatment of chronic hepatitis B, with this drug seemed capable of reducing HBV-DNA serum levels by a mean of 50

2001 International journal of clinical pharmacology and therapeutics

484. Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia

Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia Huse D M, Schainbaum S, Kirsch A J, Tyring S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Famciclovir therapy for reducing the duration of post-herpetic neuralgia (PHN). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Immunocompetent adults with uncomplicated herpes zoster, diagnosed within 72 hours of onset of rash. Setting Primary care centres in the US, Canada and Australia. Dates to which data relate

1997 NHS Economic Evaluation Database.

485. Is there any evidence for the use of famciclovir in cutaneous H Simplex infections ie H Labialis?

Is there any evidence for the use of famciclovir in cutaneous H Simplex infections ie H Labialis? Is there any evidence for the use of famciclovir in cutaneous H Simplex infections ie H Labialis? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe (...) across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence for the use of famciclovir in cutaneous H Simplex infections ie H Labialis? We found little evidence to support the use of famciclovir in the prevention or treatment of herpes

2006 TRIP Answers

486. If a rugby player is getting recurrent attacks of scrumpox currently treated with Famciclovir 750mg daily for 1 week - is there evidence for the benefits of more longterm prophylactic antivirals?

If a rugby player is getting recurrent attacks of scrumpox currently treated with Famciclovir 750mg daily for 1 week - is there evidence for the benefits of more longterm prophylactic antivirals? If a rugby player is getting recurrent attacks of scrumpox currently treated with Famciclovir 750mg daily for 1 week - is there evidence for the benefits of more longterm prophylactic antivirals? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only (...) If a rugby player is getting recurrent attacks of scrumpox currently treated with Famciclovir 750mg daily for 1 week - is there evidence for the benefits of more longterm prophylactic antivirals? We searched the NLH Specialist Library for Skin Conditions and the TRIP and Medline databases but found no guidance on the management of recurrent scrum pox/herpes simplex of the skin. The BNF offers the following general prescribing information for famciclovir: “ Indications: treatment of herpes zoster, acute

2006 TRIP Answers

487. Is there any evidence that use of aciclovir/famciclovir reduces the risk of postherpetic neuralgia after shingles?

Is there any evidence that use of aciclovir/famciclovir reduces the risk of postherpetic neuralgia after shingles? Is there any evidence that use of aciclovir/famciclovir reduces the risk of postherpetic neuralgia after shingles? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere (...) clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence that use of aciclovir/famciclovir reduces the risk of postherpetic neuralgia after shingles? Clinical Evidence contains a chapter on postherpetic neuralgia (1

2008 TRIP Answers

488. Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00098046 Recruitment Status : Completed First Posted : December 3, 2004 Last Update Posted : September 26

2004 Clinical Trials

489. Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection

Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00098059 Recruitment Status : Completed First Posted : December 3, 2004 Results First Posted : May 6, 2009 Last Update

2004 Clinical Trials

490. A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00129818 Recruitment Status : Completed First Posted : August 12, 2005 Last Update Posted : April 27, 2012 Sponsor: Novartis Information provided by: Novartis Study Details

2005 Clinical Trials

491. Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection

Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00448227

2007 Clinical Trials

492. Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2006 Clinical Trials

493. RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00219310 Recruitment Status : Completed First Posted : September 22, 2005 Last Update Posted : April 27, 2012 Sponsor: Novartis Information provided

2005 Clinical Trials

494. A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis

A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00248144

2005 Clinical Trials

495. Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00171990 Recruitment Status : Completed First Posted : September 15, 2005 Last Update Posted : August 15, 2013 Sponsor: Novartis Information

2005 Clinical Trials

496. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. (Abstract)

Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. This was a double-blind, randomized multicentre trial comparing efficacy and safety of brivudin (125 mg, once a day) and famciclovir (250 mg, three times a day), both given orally for 7 days, in the treatment of herpes zoster.A total of 2027 immunocompetent zoster patients>or=50 years with zoster-related (...) pain at presentation were included. Outcome measures embraced prevalence of postherpetic neuralgia (PHN), defined as at least moderate pain 3 months after treatment initiation, duration of PHN, prevalence and duration of zoster-associated pain (ZAP), duration of vesicle formation and rash healing.The prevalence of PHN at month 3 was 11.3% with brivudin and 9.6% with famciclovir [per-protocol (PP) population]. Equivalence of the two drugs could be demonstrated (P=0.01, PP and intention-to-treat

2005 Journal of the European Academy of Dermatology and Venereology : JEADV Controlled trial quality: predicted high

497. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. (Abstract)

Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Daily antiviral therapy with famciclovir and valacyclovir has been shown to be effective in reducing both symptomatic and asymptomatic reactivation of herpes simplex virus type 2 (HSV-2) when compared to placebo. However, few comparative studies between the 2 antivirals have been performed.To compare the clinical and virologic effects of famciclovir and valacyclovir administered (...) as daily suppressive therapy for persons with genital herpes.Two randomized, double-blind, placebo-controlled studies comparing daily famciclovir 250 mg bid with valacyclovir 500 mg qd were performed. Study 1 randomized 320 participants and compared the clinical effect of the drugs given for 16 weeks, and study 2 enrolled 70 HSV-2 seropositive subjects and compared the virologic effect of the drugs given for 10 weeks.In study 1, the time to first recurrence was similar in famciclovir and valacyclovir

2006 Sexually transmitted diseases Controlled trial quality: predicted high

498. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. (Full text)

Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Orally administered antiviral therapy for genital herpes improves the time to lesion healing and resolves symptoms during an outbreak. Although traditional therapy for a recurrent episode for healthy adults has consisted of twice-daily dosing for 5 days, recent studies have indicated that shorter courses of antiviral therapy are effective. This study (...) was conducted to assess the efficacy and safety of a patient-initiated, single-day regimen of famciclovir therapy, compared with placebo, in immunocompetent adult patients with recurrent genital herpes.This multicenter, multinational, randomized, double-blind, parallel-group, placebo-controlled study compared single-day, patient-initiated oral famciclovir (1000 mg given twice daily) with placebo for the treatment of recurrent genital herpes. Patients were instructed to initiate therapy within 6 h after

2006 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Controlled trial quality: predicted high PubMed abstract

499. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. (Abstract)

Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. The brief period of viral replication in recurrent herpes labialis lesions suggests shorter therapeutic regimens are a logical episodic treatment strategy.We sought to assess the efficacy and safety of single-dose and single-day famciclovir treatments.In all, 701 randomly assigned patients self-initiated therapy with famciclovir (1500 mg once [single dose (...) ] or 750 mg twice a day for 1 day [single day]) or placebo within 1 hour of onset of the prodromal symptoms of an episode of herpes labialis. Lesion healing was monitored by diaries and frequent clinic visits.Median healing times of primary (first to appear) vesicular lesions in the famciclovir single-dose, famciclovir single-day, and placebo groups were 4.4, 4.0, and 6.2 days, respectively. There was no significant difference between the famciclovir regimens. Adverse events in the famciclovir groups

2006 Journal of the American Academy of Dermatology Controlled trial quality: predicted high

500. [Clinical investigation of famciclovir in chronic hepatitis B patients irresponsive to alpha interferon treatment]. (Abstract)

[Clinical investigation of famciclovir in chronic hepatitis B patients irresponsive to alpha interferon treatment]. To evaluate the efficacy and safety of famciclovir on the decreasing levels of serum HBV-DNA and ALT and HBeAg/antiHBe seroconversion in chronic hepatitis B patients irresponsive to 3 months treatment with alpha interferon.Two hundred and nineteen patients with chronic HBV infection, defined as positive HBsAg, HBeAg and HBV DNA, were enrolled and randomly half-and- half put (...) into famciclovir and placebo groups. The two groups received either famciclovir 500 mg tid or a placebo treatment for 24 weeks, and then were followed-up for another 24 weeks with no treatment.At the end of 24 weeks, the log value of HBV DNA dropped from 6.54+/-1.26 to 5.70+/-2.03 in the famciclovirt group and were elevated from 6.30+/-1.32 to 6.51+/-1.65 in the placebo group (P < 0.01). The rate of cases with persistence HBV DNA dropped 2 log of quantity in the famciclovir group and was 28.28% (28/99

2005 Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>